[go: up one dir, main page]

WO2019234677A3 - Biomarkers for non-invasive early diagnosis of infectious diseases - Google Patents

Biomarkers for non-invasive early diagnosis of infectious diseases Download PDF

Info

Publication number
WO2019234677A3
WO2019234677A3 PCT/IB2019/054716 IB2019054716W WO2019234677A3 WO 2019234677 A3 WO2019234677 A3 WO 2019234677A3 IB 2019054716 W IB2019054716 W IB 2019054716W WO 2019234677 A3 WO2019234677 A3 WO 2019234677A3
Authority
WO
WIPO (PCT)
Prior art keywords
biomarkers
early diagnosis
infectious diseases
invasive early
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2019/054716
Other languages
French (fr)
Other versions
WO2019234677A2 (en
Inventor
Luisa Pecorari
Gianfranco Mario Emilio GILARDELLI
Anna IANNONE
Elena Rossi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to EP19736814.5A priority Critical patent/EP3803393A2/en
Publication of WO2019234677A2 publication Critical patent/WO2019234677A2/en
Publication of WO2019234677A3 publication Critical patent/WO2019234677A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4713—Plasma globulins, lactoglobulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)

Abstract

The present invention relates to a method for non-invasive early diagnosis of infectious diseases, in particular mastitis, in a subject, by determining in a sample of biological fluid, in particular lacrimal fluid, from said subject the amount of at least two biomarkers selected from a panel, and comparing said amounts with the corresponding reference values. The combined variation in the amount of each of said biomarkers compared with the corresponding reference value indicates the onset of the infectious disease.
PCT/IB2019/054716 2018-06-08 2019-06-06 Biomarkers for non-invasive early diagnosis of infectious diseases Ceased WO2019234677A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP19736814.5A EP3803393A2 (en) 2018-06-08 2019-06-06 Biomarkers for non-invasive early diagnosis of infectious diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102018000006170 2018-06-08
IT102018000006170A IT201800006170A1 (en) 2018-06-08 2018-06-08 BIOMARCATORS FOR EARLY NON-INVASIVE DIAGNOSIS OF INFECTIOUS DISEASES

Publications (2)

Publication Number Publication Date
WO2019234677A2 WO2019234677A2 (en) 2019-12-12
WO2019234677A3 true WO2019234677A3 (en) 2020-03-12

Family

ID=63579612

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2019/054716 Ceased WO2019234677A2 (en) 2018-06-08 2019-06-06 Biomarkers for non-invasive early diagnosis of infectious diseases

Country Status (3)

Country Link
EP (1) EP3803393A2 (en)
IT (1) IT201800006170A1 (en)
WO (1) WO2019234677A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120045778A1 (en) * 2010-08-23 2012-02-23 The Ohio State University Research Foundation Elisa for haptoglobin-matrix metalloproteinase 9 complex as a diagnostic test for conditions including acute inflammation
WO2013014669A1 (en) * 2011-07-24 2013-01-31 Carmel-Haifa University Economic Corp. Lactoferrin fragments and use thereof
CA2988833A1 (en) * 2015-06-10 2016-12-15 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. Method and apparatus for monitoring the state of health of dairy cows

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120045778A1 (en) * 2010-08-23 2012-02-23 The Ohio State University Research Foundation Elisa for haptoglobin-matrix metalloproteinase 9 complex as a diagnostic test for conditions including acute inflammation
WO2013014669A1 (en) * 2011-07-24 2013-01-31 Carmel-Haifa University Economic Corp. Lactoferrin fragments and use thereof
CA2988833A1 (en) * 2015-06-10 2016-12-15 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. Method and apparatus for monitoring the state of health of dairy cows

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BOEHMER J L ET AL: "Proteomic Analysis of Differentially Expressed Proteins in Bovine Milk During Experimentally Induced Escherichia coli Mastitis", JOURNAL OF DAIRY SCIENCE, AMERICAN DAIRY SCIENCE ASSOCIATION, US, vol. 91, no. 11, 1 November 2008 (2008-11-01), pages 4206 - 4218, XP026955103, ISSN: 0022-0302, [retrieved on 20081101] *
CARLA DUARTE ET AL: "Technological advances in bovine mastitis diagnosis: an overview", JOURNAL OF VETERINARY DIAGNOSTIC INVESTIGATION, vol. 27, no. 6, 1 January 2015 (2015-01-01), pages 665 - 672, XP055450209 *
CARLO DE OLIVEIRA MARTINS ET AL: "Distinct Mitral Valve Proteomic Profiles in Rheumatic Heart Disease and Myxomatous Degeneration", CLINICAL MEDICINE INSIGHTS: CARDIOLOGY, vol. 8, 1 January 2014 (2014-01-01), XP055524234, ISSN: 1179-5468, DOI: 10.4137/CMC.S17622 *
JINMING HUANG ET AL: "iTRAQ-proteomics and bioinformatics analyses of mammary tissue from cows with clinical mastitis due to natural infection with Staphylococci aureus", BMC GENOMICS, BIOMED CENTRAL, vol. 15, no. 1, 2 October 2014 (2014-10-02), pages 839, XP021199100, ISSN: 1471-2164, DOI: 10.1186/1471-2164-15-839 *
KALMUS P ET AL: "Milk haptoglobin, milk amyloid A, and N-acetyl-[beta]-D-glucosaminidase activity in bovines with naturally occurring clinical mastitis diagnosed with a quantitative PCR test", JOURNAL OF DAIRY SCIENCE, AMERICAN DAIRY SCIENCE ASSOCIATION, US, vol. 96, no. 6, 1 June 2013 (2013-06-01), pages 3662 - 3670, XP002759760, ISSN: 0022-0302, [retrieved on 20130330], DOI: 10.3168/JDS.2012-6177 *
SHOAIB ASHRAF ET AL: "Clumping factor A of Staphylococcus aureus interacts with AnnexinA2 on mammary epithelial cells", SCIENTIFIC REPORTS, vol. 7, no. 1, 19 January 2017 (2017-01-19), XP055524226, DOI: 10.1038/srep40608 *

Also Published As

Publication number Publication date
WO2019234677A2 (en) 2019-12-12
IT201800006170A1 (en) 2019-12-08
EP3803393A2 (en) 2021-04-14

Similar Documents

Publication Publication Date Title
WO2020123316A3 (en) Methods for determining a location of a biological analyte in a biological sample
WO2018209361A3 (en) Universal early cancer diagnostics
WO2018007872A9 (en) Biomarkers for inflammatory bowel disease
CA3010517A1 (en) Method for evaluating the health status of an individual
WO2015193325A3 (en) Ceramides and their use in diagnosing cvd
BR112016018116A2 (en) antibody and sequences specific for e.g. coli, pharmaceutical or diagnostic preparation comprising them, use of the antibody to treat e.g. coli and diagnosing the disease, antibody-encoding nucleic acid, an expression cassette, plasmid or host cell comprising the same, and method of production
WO2018038352A3 (en) Autoantibody biomarker for diagnosing dementia and method for diagnosing dementia by using same
WO2019126556A3 (en) Theranostic test for antifungal treatment of inflammatory diseases
JP2017508144A5 (en)
WO2017165766A3 (en) Biomarkers of proteopathies and uses thereof
WO2020213969A3 (en) Biomarker for diagnosing corneal endothelial cell dysfunction
MX2019012439A (en) DIAGNOSTIC TOOL TO DETERMINE THE ERASE OF THE PROCESS OF THE FOOT OF THE PODOCYTE.
WO2010138610A3 (en) Novel desmin phosphorylation sites useful in diagnosis and intervention of cardiac disease
WO2015200887A3 (en) Method for diagnosing subclinical and clinical acute rejection by analysis of predictive gene sets
WO2019234677A3 (en) Biomarkers for non-invasive early diagnosis of infectious diseases
WO2015006657A3 (en) Method for the diagnosis and prognosis of cancer
WO2020115270A3 (en) Biomarker for detecting zearalenone effect
WO2018236134A3 (en) Method and kit for diagnosis of muscle weakness-related diseases using blood biomarker
EP3492607A3 (en) Urinary mirnas for the in vitro diagnosis of bladder cancer
BR112022012010A2 (en) ANTIBODIES, ISOLATED NUCLEIC ACID, HOST CELL, PHARMACEUTICAL FORMULATION, USE OF THE ANTIBODY, METHOD OF PRODUCTION OF AN ANTIBODY, METHOD OF TREATMENT OF AN INDIVIDUAL THAT HAS CANCER, AND METHOD OF TREATMENT OF AN INDIVIDUAL THAT HAS AN INFLAMMATORY OR AUTOIMMUNE DISEASE
WO2020086810A3 (en) Methods of using histatin for diagnosing and treating a dry eye disease or other ocular diseases
WO2014197460A8 (en) Methods for diagnosing and treating bicuspid aortic valve and/or aortopathies
CA2984732C (en) In vitro diagnostic method for alzheimer's disease, based on the albumin redox level in the cerebrospinal fluid
WO2017059276A8 (en) Therapeutic and diagnostic methods for autoimmune diseases and/or inflammation
WO2015158608A3 (en) Diagnosis of chronic kidney disease by quantitative analysis of post-translational modifications of plasma proteins

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19736814

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2019736814

Country of ref document: EP

Effective date: 20210111